Table 2.
Characteristics of the Study Participants With and Without Squamous Intraepithelial Lesions at Baseline
| SIL at baseline, n = 122 (24.7%) | No SIL at baseline, n = 362 (74.4%) | p | |
|---|---|---|---|
| Age, in years | 37 (17) | 39 (17) | 0.188 |
| Current smoker | 58 (47.9%) | 155 (43.4%) | 0.388 |
| Time since HIV diagnosis, in years | 9 (9.25) | 9 (9.5) | 0.612 |
| Any history of an AIDS-defining illness | 28 (23.0%) | 46 (12.7%) | 0.007 |
| Baseline CD4+ lymphocyte count, cells/μL | 700 (542) | 650 (374) | 0.316 |
| Nadir CD4+ lymphocyte count, cells/μL | 339 (321) | 345 (249) | 0.047 |
| Nadir CD4+ lymphocyte count <200 cells/μL | 38 (31.7%) | 75 (21.2%) | 0.021 |
| HCV positive antibodies | 8 (6.6%) | 10 (2.8%) | 0.091 |
| Previous diagnosis of any STI | 88 (72.1%) | 253 (69.9%) | 0.639 |
| Syphilis | 51 (41.8%) | 176 (48.5%) | 0.192 |
| Gonorrhea | 19 (15.6%) | 60 (16.6%) | 0.796 |
| Chlamydia trachomatis infection | 10 (8.2%) | 25 (6.9%) | 0.639 |
| Anogenital condyloma acuminate | 50 (41.0%) | 97 (26.8%) | 0.003 |
| Baseline HR-HPV | 115 (94.3%) | 271 (74.9%) | <0.001 |
| Baseline HPV-16 | 63 (51.6%) | 103 (28.5%) | <0.001 |
| Baseline HPV-18 | 29 (23.8%) | 42 (11.6%) | 0.002 |
| Baseline pHR-HPV | 106 (86.9%) | 249 (68.8%) | <0.001 |
Qualitative variables are expressed as total numbers and percentages; quantitative variables are expressed as medians and interquartile ranges.
HCV, hepatitis C virus; HIV, human immunodeficiency virus; HPV, human papillomavirus; HR-HPV, high-risk HPV; pHR-HPV, pooled high-oncogenic risk human papillomavirus; SIL, squamous intraepithelial lesion; STI, sexually transmitted infection.